CD274 and non-small cell lung carcinoma: For non-small cell lung cancer (NSCLC), a multi-omics analysis combining circulating immune and gut microbiome data identified key factors affecting progression-free survival (PFS), optimizing first-line therapy for PD-L1 low-expression patients [191].